Skip to main content

Table 4 Comparison of characteristics between the training group and validation group

From: Construction and validation of a prediction model for the risk of citrate accumulation in patients with hepatic insufficiency receiving continuous renal replacement therapy with citrate anticoagulation

Characteristics

training group (n = 187)

validation group(n = 66)

Z/χ2

P-value

Age (years)

56(46, 66)

60.5(47.5,71)

−1.591

0.112

Male【n(%)】

128(68.4)

45(68.2)

0.002

0.968

Hepatic dysfunction classification 【n(%)】

  

2.447

0.654

acute hepatic failure

52(27.8)

23(34.8)

  

subacute hepatic failure

3(1.6)

0(0)

  

acute-on-chronic hepatic failure

37(19.8)

12(18.2)

  

chronic hepatic failure

34(18.2)

13(19.7)

  

hepatic dysfunction

61(32.6)

18(27.3)

  

Indications for CRRT 【n(%)】

  

1.424

0.491

CKD

11(5.9)

5(7.6)

  

AKI

129(69)

49(74.2)

  

Others

47(25.1)

12(18.2)

  

BMI (kg/m^2)

22.7(20.3,25.60)

23.6(20.76,27)

−1.324

0.186

Weight (kg)

62.75(55,70)

63(55, 73)

−0.655

0.513

Map (mmHg)

81(74,89)

82(75.5,91)

−1.059

0.290

Norepinephrine (ug/kg/min)

0.02(0, 0.16)

0.01(0,0.11)

−0.328

0.743

Alb (g/L)

33.1(29.3,36.6)

32.65(29.68,36.78)

−0.259

0.795

AST (U/L)

127(53, 438)

181.5(72,478)

−1.068

0.285

ALT (U/L)

102(33, 387)

127(39,479.5)

−0.751

0.452

LDH (U/L)

399(284,758)

506(288,906.25)

−1.139

0.255

Tbil (umol/L)

130(57,257)

113.4(48.88,249.43)

−1.033

0.302

CRP (mg/L)

53.26(20.15,101.55)

57.35(20.98,106.15)

−0.241

0.810

WBC(*10^9/L)

9.65(6.5,15.24)

9.3(5.9,12.2)

−0.732

0.464

PLT(*10^9/L)

46(29,106)

59(32,90)

−0.743

0.458

Hb(g/L)

73(62,93)

78(64,94)

−0.867

0.386

PT(s)

18.1(14.6,24.3)

17.4(15.13,22.65)

−0.170

0.865

INR

1.64(1.28,2.22)

1.52(1.28,1.91)

−1.017

0.309

APTT(s)

44.1(33.2,60.1)

40.75(33.23,55.3)

−0.967

0.334

serum potassium (mmol/L)

4.32(4,4.67)

4.26(3.93,4.76)

−0.766

0.438

tCa (mmol/L)

2.25(2.17,2.25)

2.23(2.15, 2.30)

−1.423

0.155

Scr (umol/L)

168(87,255)

153(82.75, 287.75)

−0.217

0.828

BUN (mmol/L)

14.6(7.9,14.6)

13.8(8.10,26.45)

−0.484

0.629

pH

7.43(7.38,7.47)

7.42(7.36,7.47)

−0.776

0.438

PO2 (mmHg)

106(89,132)

103(82.6123.3)

−1.445

0.148

PCO2 (mmHg)

34.8(31.6,39.2)

33.1(28.93,38.05)

−2.009

0.045

Bicarbonate concentration (mmol/L)

23.16 ± 3.8

22.16 ± 4.20

1.784

0.076

BE (mmol/L)

−1.15 ± 4.13

−2.03 ± 4.74

1.422

0.156

Lactate (mmol/L)

1.9(1.3,3.1)

1.8(1.28,2.58)

−0.569

0.570

iCa (mmol/L)

1.12(1.04,1.18)

1.1(1.03,1.16)

−0.668

0.504

Dialysate flow rate (ml/h)

1000(1000,2000)

1000(1000,2000)

−1.261

0.207

citrate concentration (mmol/L)

3 (2,3)

3(2,3)

−1.286

0.198

  1. CRR continuous renal replacement therapy, AKI acute kidney injury, CK chronic kidney disease, BMI body mass index, MAP mean arterial pressure, Alb albumin, ALT alanine aminotransferase, AST aspartate aminotransferase, Tbil total bilirubin, LDH lactate dehydrogenase, WBC white blood cell count, Hb hemoglobin, PLT platelet count, CRP C-reactive protein, APTT activated partial thromboplastin time, PT prothrombin time, INR international normalized ratio, Scr serum creatinine, BUN blood urea nitrogen, tCa total calcium concentration, PO2 partial pressure of oxygen: PCO2 partial pressure of carbon dioxide, BE Base excess, iCa ionized calcium concentration